Introduction: The search for a reliable neuroimaging biomarker in Alzheimer's disease is a matter of intense research. The presence of cerebral microbleeds seems to be a potential biomarker. However, it is not clear if the presence of microbleeds has clinical usefulness to differentiate mild Alzheimer's disease and amnestic mild cognitive impairment from normal aging. We aimed to verify if microbleed prevalence differs among three groups: mild Alzheimer's disease, amnestic mild cognitive impairment due to Alzheimer's disease, and normal controls. Moreover, we studied whether microbleeds were associated with apolipoprotein E allele "4 status, cerebrospinal fluid amyloid-beta, total and phosphorylated tau protein levels, vascular factors, and cognition. Methods: Twenty-eight mild Alzheimer's disease patients, 34 with amnestic mild cognitive impairment and 36 cognitively normal elderly subjects underwent: magnetic resonance imaging with a susceptibility-weighted imaging sequence on a 3T scanner, apolipoprotein E genotyping and a full neuropsychological evaluation. Only amnestic mild cognitive impairment and mild Alzheimer's disease underwent cerebrospinal fluid analysis. We compared the groups and verified if microbleeds were predicted by all other variables. Results: Mild Alzheimer's disease presented a higher prevalence of apolipoprotein E allele "4 in relation to amnestic mild cognitive impairment and control group. No significant differences were found between groups when considering microbleed presence. Logistic regression tests failed to find any relationship between microbleeds and the variables. We performed three different regression models using different independent variables: Model 1 -amyloid-beta, phosphorylated tau protein, total tau, apolipoprotein E allele "4 status, age, and sex; Model 2 -vascular risk factors, age, and sex; Model 3cognitive scores sex, age, and education. Conclusion: Although microbleeds might be related to the Alzheimer's disease process, their presence is not a good candidate for a neuroimaging biomarker of the disease, especially in its early phases.
Introduction
Alzheimer's disease (AD) is the most common neurodegenerative diseases and is characterized by cognitive and neuropsychiatric problems which lead to functional dependence. According to the Alzheimer's Association, 1 AD is among the top 10 causes of death in the last decade in the USA, and deaths attributed to AD increased 71%, while those attributed to all of the other most common causes have decreased their incidence. In this sense, the search for biomarkers that could improve diagnostic accuracy in the earliest disease phase is a matter for intense research. Structural neuroimaging has contributed with different and relevant methods such as brain volumetry, cortical thickness, voxel-based morphometry, diffusion tensor imaging techniques, among others.
In this context, cerebral microbleeds (MBs) have become a matter of research in the AD field, especially because they could combine different aspects of the pathophysiology of the disease such as vascular and amyloidosis hypotheses. Excessive and abnormal accumulation of extracellular neuritic plaques (NPs), composed of amyloid-beta (Ab , is thought to be one of the main pathological mechanisms of AD, together with the presence of neurofibrillary tangles (NFTs) and decreased synaptic density. 2 Ab 1-42 peptides can also be deposited in the intravascular space causing cerebral amyloid angiopathy (CAA). Their progressive deposition in medial and adventitial layers of arteries, arterioles and brain capillaries, increases the chance of spontaneous MBs, 3 most commonly with lobar distribution (cortical-subcortical regions and cerebellum). 4, 5 The anatomical co-occurrence of NP and CAA is common, both arising from the accumulation of Ab in the brain, which makes lobar MBs a potential indicator of amyloidosis in patients in the AD spectrum. 6, 7 The presence of apolipoprotein E allele "4 (APOE "4) is another common risk factor for AD and CAA, and may be related to Ab 1-42 metabolism and MBs. In transgenic mice apolipoprotein E (APOE) knockout, for example, the deposition of Ab in the form of NP and CAA showed considerably reductions, indicating a possible influence of APOE protein on this process. 8 The Rotterdam Scan Study 5 demonstrated that, even in healthy older individuals, there is an association between lobar MBs and APOE "4, which is in agreement with increased APOE "4 frequencies seen in patients with ''probable CAA''.
However, other factors, such as arterial hypertension and diabetes, contribute to cerebral MBs in AD. 9, 10 When in association with hypertension, MBs distribution is most common in basal ganglia, thalamus, brainstem, and cerebellum, 11 and lobar (mainly occipital lobe) when they are associated with amyloid angiopathy.
Regarding the effect of MBs on cognitive functions, it is more clear in vascular dementia than in AD, 12 and the association between MBs and neuropsychological performance in AD patients is contradictory. [13] [14] [15] Despite these close relationships between the pathophysiology of AD and MBs, it is not entirely clear if the presence of MBs has clinical usefulness to differentiate dementia (especially in the mild phase) and amnestic mild cognitive impairment (aMCI), a possible prodromal AD, from normal aging. Therefore, in this study, we aimed to verify if there are differences in the prevalence of MBs in three groups: mild dementia due to AD, aMCI due to AD and normal controls. In addition, we studied if MBs were associated with APOE "4 status, cerebrospinal fluid (CSF) Ab 1-42 , total and phosphorylated tau (t-tau and p-tau), vascular risk factors and cognition in these groups.
Methods Subjects
We studied 98 subjects: 28 patients with mild AD, 34 with aMCI and 36 cognitive normal older adults. The patients (mild AD) were recruited from the Neuropsychology and Dementia clinic, Hospital de Clı´nicas, University of Campinas. The aMCI patients and cognitively normal older adults were invited to participate in the project in order to check their memory.
The diagnosis of dementia due to AD fulfilled the National Institute of Aging and Alzheimer's Association (NIA/AA) 16 and all AD patients had a Clinical Dementia Rating (CDR) 6 score of 0.5 or 1. aMCI patients were diagnosed using the core criteria of the NIA/AA for MCI 17 and had pathophysiological evidence of AD (Ab 1-42 < 416 pg/ml) and/or low Ab 1-42 / p-tau (<9.53). 18 All aMCI participants had a CDR score of 0.5 (with an obligatory memory score of 0.5). CDR was performed using a semi-structured interview.
Controls were identified as cognitively normal: they did not exhibit any neurological or psychiatric disorders or require psychoactive medication; they performed as normal in the Mini Mental State Examination (MMSE), considering age and education; 19 and their structural images were normal. The control group had no memory complaints, performed as normal on neuropsychological tests and had a CDR score of zero.
Exclusion criteria for all subjects: other neurological or psychiatric diseases or a head injury with loss of consciousness; use of sedative drugs in the last 24 h before the neuropsychological assessment, drug or alcohol addiction, prior chronic exposure to neurotoxic substances, Fazekas scale>1 20 and Hachinski ischemic score>4. 21 The Medical Research Ethics Committee of UNICAMP Hospital approved this study, and written informed consent form (either from the subjects or from their responsible caretakers, if incapable) was obtained from all participants before study initiation, according to the Declaration of Helsinki. Pre-diagnostic procedures also comprised laboratory tests including Vitamin B12, folate, and thyroid hormones.
Neuropsychological, functional and neuropsychiatric assessment
An neuropsychologist of six-years experience (AFMCC), blinded to the biomarkers data, performed the neuropsychological evaluations. Global cognitive status was measured by MMSE; 22 episodic memory by the Rey Auditory Verbal Learning Test (RAVLT; sub-items encoding, delayed recall -A7, and recognition -RC-FP); 23 attention/working memory by forward digit span (FDS) and backward digit span (BDS). For visual perception, we used the following tests: subtests of Luria's Neuropsychological Investigation (LNI), 24 using items G12, G13, G14 and G17 (item from Raven's test), one item for mental rotation of figures 25 and a copy of the Rey-Osterrieth Complex Figure Test . 26 For executive functions we used the Trail Making Test A (TMT-A), and B (TMT-B), 27 the Stroop test (congruent -Stroop C, and incongruent -Stroop I) 28 and Clock Drawing Test (CDT). 26 Language tests included the Boston Naming Test (BNT), 29 semantic verbal fluency (SVF) -for category (animals), and phonological fluency (PVF) for letters (items beginning with F, A, S in one minute for each letter); 30 neuropsychiatric symptoms were evaluated by neuropsychiatric inventory (NPI). 31 Functional performance was measured by CDR and Pfeffer functional activities questionnaire. 32 
Vascular risk factors assessment
Information about vascular risk factors (arterial hypertension, diabetes and dyslipidemia) of the participants was obtained during the interview or accessed in their medical report.
Image acquisition
All magnetic resonance (MR) images were acquired on a 3.0 T magnetic resonance imaging (MRI) Philips Achieva scanner. The following protocol was applied to each subject: 
Blood and CSF sample collection and handling
Peripheral blood samples collected from the three groups were centrifuged at 2500 rpm for 10 min, then the serum was, subsequently, aliquoted in 1 ml Eppendorf microtube and stored at À80 C until analysis. CSF samples, only from aMCI and AD patients, were collected by lumbar puncture and stored in a polypropylene tube of 1 ml. Then the samples were centrifuged at 700 rpm for 10 min and stored at À80 C until analysis.
CSF biomarkers quantification. Dosages of Ab 1-42 , t-tau and p-tau were carried out with amyloid-b INNOTEST kits (1-42), h-TAU INNOTEST Ag and INNOTEST Phospho-tau (181 P) (INNO-BIA AlzBio3, Fujirebio, USA), based on enzyme immunoassay solid phase. This multiparameter immunoassay allows the simultaneous quantification of Aß1-42, t-tau, and p-tau181P in CSF using xMAP technology. Suspensions with immunoglobulins against Ab 1-42 , t-tau and p-tau were added under inert surface plates, previously washed. A mixture containing CSF samples of research subjects and monoclonal antibodies -to recognize specific immunoglobulins on the plateswas added and incubated for one night, and protected from light exposure. The plates were then washed and subsequently added to streptavidin-phycoerythrin. The set was incubated for one hour. A scanning solution (phosphate buffer saline) was added to the plates following a final wash. Finally, the immunoassay was analyzed to quantify biomarkers.
Genotyping of the APOE gene. Genomic DNA for genotyping the main APOE polymorphisms was extracted from leukocytes obtained from peripheral blood. The presence/absence of haplotypes was either determined by differential amplification with the three specific amplification setups for "2, "3, or "4 allele. This genotyping analysis was performed by polymerase chain reaction (PCR) in real time.
Statistical analysis
We used IBM's SPSS software (Version 21, SPSS Inc., Chicago, Illinois, USA) for statistical analysis. We first performed the Kolmogorov-Smirnov to test for normality. All variables (MBs, Ab 1-42 , p-tau, t-tau, APOE "4 status, neuropsychological and demographic data) were compared between the groups. When data followed a normal distribution, we performed parametric tests; otherwise, we used non-parametric tests. Results were considered significant when p < 0.05, corrected for multiple comparisons (Tukey test).
Initially, we intended to use the number of MBs as a continuous variable, since our hypothesis was that there would be a significant variance between individuals and between groups. However, we found a small variance of MBs (over 90% of the sample had up to two MBs). Thus, we chose to consider this variable as categorical: presence or absence of MBs and used the chi-square test for comparisons between groups. We also considered vascular risk factors as a categorical variable (presence of at least one factor or absence).
In order to verify if MBs were predicted by the variables of the study, we decided to perform logistic regression considering MBs as the dependent variable, in three different models: Model 1, Ab1-42, p-tau, t-tau, APOE "4 status, age and sex were considered independent variables; Model 2, vascular risk factors (arterial hypertension, diabetes, dyslipidemia) and age and sex as independent variables; Model 3, cognitive scores (episodic memory, visuospatial abilities, executive functions, and language tests), sex, age and education were used as independent variables. All analyses were done considering both the groups separately and together.
Results
Demographics and neuropsychological data are shown in Table 1 . Mild AD patients were older and had less years of education than controls, but not in relation to aMCI. These variables were included as covariates in all the subsequent analysis.
We did not find significant differences between the groups when considering the presence of MBs as well as dosages of Ab 1-42, p-tau and t-tau between aMCI and mild AD. Mild AD patients had a higher prevalence of APOE "4 in relation to controls and aMCI groups ( Table 2 ). Comparing vascular risk factors, there was no difference regarding any variables between the groups.
We conducted Fisher exact tests to assess whether there were differences in relation to MBs between the three groups given the presence of APOE "4 ( Table 3 ). We did not find significant differences between the groups. We also used Fisher exact test to analyze if there were intra-group differences considering the presence of the APOE "4 and MBs. In the same way, we did not find intra-group differences ( Table 3) .
To verify if MBs were predicted by the other variables of the study, we performed different logistic regression tests always considering MBs as the dependent variable. In the first regression model, Ab 1-42 , p-tau, t-tau, APOE "4 status, age, and sex were considered independent variables. In the second regression model, the independent variables were vascular risk factors (arterial hypertension, diabetes, dyslipidemia, age, and sex). In the last regression, cognitive scores (episodic memory, visuospatial abilities, executive functions, and language tests), sex and age were set as independent variables. We considered, for the analysis, both groups separately and together. There were no statistically significant results in any of the tests (for more details, see Appendix 1).
Discussion
One of the most relevant objectives in AD research is to find highly sensitive and specific biomarkers, especially before dementia is fully developed. In this sense, neuroimaging has been contributing with several different methods and approaches. The study of MBs as biomarkers has the theoretical advantage of combining different and complementary pathophysiological aspects of AD, such as amyloid and vascular hypotheses. However, our study did not detect any differences in the prevalence of MBs between normal aging, aMCI due to AD and mild dementia due to AD as well as any relationship between MBs and the most well established AD biomarkers and with cognition. The MBs incidence in AD is around 23% of the cases (range of 17-31%), 33 as only one MB presented in half of the patients and the other half with two or more brain MBs. According to Sepehry et al., 34 in a review that considered multiple population-based studies, the prevalence of MBs in cognitively normal older adults aged 60-69 years is 15-17% when evaluated by the SWI method. The prevalence found here was 16.66%. It is important to note that SWI has twice the sensitivity for detection of MBs than T2*-GRE acquisition. 34 Although the MBs prevalence in our AD and aMCI patients was higher than in our controls, it did not reach statistical significance, even considering that our AD patients were older than controls. According to the same authors, the prevalence in cognitively normal older adults in the range of 70-79 years old is 30-31%. 34 The prevalence in our AD patients (average 73 years old) was 25%, lower than that reported by the author. In the same way, Shams et al. 35 evaluated 1504 patients (age 63 AE 10 years) with different diagnoses of dementia and found a prevalence of MBs of 22%.
Regarding the association between MBs, Ab 1-42 and APOE "4, we also did not find significant results. It is important to state that our results in relation to Ab 1-42 levels and APOE "4 prevalence are consistent with the literature. 18, 36 However, other recent studies with larger sample sizes found an association between MBs and Ab 1-42 . 15, 35 Chiang et al. 15 found this association only when the number of MBs was greater than three. They also found an association with CSF p-tau. Regarding APOE "4, other authors failed to demonstrate an association with MBs. 13, 37, 38 In a study comparing patients with AD with many brain MBs and those without any MB, patients with many brain MBs were more likely to be homozygous for APOE "4. 14 In addition, gender may influence the presence of MBs. Cacciottolo et al. 39 found that only men with MCI and AD showed a higher risk of MBs.
An additional aspect that may be related to both AD and MBs is of vascular risk factors such as arterial hypertension, diabetes, and dyslipidemia. Epidemiological studies indicate that elderly patients with vascular risk factors have a higher risk of developing AD. [40] [41] [42] MBs are much more common in hypertensive subjects (both in the general population and in subjects with cerebrovascular disease). Nakata-Kudo et al. 10 showed a relationship between brain MBs with arterial hypertension, and the association was weaker in AD patients than in the cerebrovascular disease population and healthy people. MBs seen in hypertensive individuals are typically located in the deep gray matter and infra-tentorial brain, whereas those seen in AD are most commonly lobar, at the corticosubcortical junction. We did not find any association between vascular risk factors and MBs. One of the possible reasons is that only three of 98 subjects had MBs in the cerebellum, brainstem, or deep gray nuclei. Another possible explanation is due to our exclusion criteria, that excluded patients with cerebrovascular disease (Fazekas > 1 and Hachinski > 4). Due to hypertension, MBs are most commonly associated with ischemic white matter disease. 43 We also did not demonstrate associations between cognition and MBs. Other authors also had similar results when considering MMSE. 10, 13, 44 However, Akoudad et al., 45 in a prospective population-based study with a much larger sample size, found that the presence of more than four MBs affected cognition in all domains and represented an increased risk for developing dementia. In our study, only four subjects (one control, two aMCI, and one AD) had more than three MBs.
The main limitation of our study was the sample size that could explain the lack of associations between MBs and the other variables. Another possible explanation for our results is that only patients with mild dementia stage (CDR ¼ 1) and patients without dementia (aMCI) were included in this study. It is possible that patients in advanced stages of the disease present more MBs and lower levels of Ab 1-42 in the CSF, which would increase this association. However, if this was true, the prevalence of MBs would not be a good option to become a biomarker in the earlier phases of the disease.
Despite the limitations, it is important to highlight that, in our sample, both mild AD and aMCI patients showed abnormal values of Ab , showing that these patients actually present the pathophysiological process of AD. Additionally, our AD patients presented a higher prevalence of APOE "4 compared with aMCI and controls. These findings (neuropsychological assessment, change in Ab 1-42 and presence of APOE "4) increase the quality of selection of our population. Moreover, MBs were evaluated by an experienced neuroradiologist using SWI protocol at 3 T, a more sensitive image contrast than T2*-GRE.
Conclusion
We suggest that, although the prevalence of MBs might be related to the AD process, it is not a good candidate for a neuroimaging biomarker of the disease. The prevalence of MBs is too small, which indicates a low sensitivity; it was not related neither to the main AD biomarkers, nor to cognition, except when larger sample sizes are studied. 
